Shares of Adaptimmune Therapeutics (NASDAQ:ADAP) have been given an average recommendation of “Hold” by the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $19.00.
ADAP has been the subject of several research reports. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, March 19th. BidaskClub lowered shares of Adaptimmune Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. ValuEngine upgraded shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Raymond James set a $20.00 target price on shares of Adaptimmune Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, Leerink Swann assumed coverage on shares of Adaptimmune Therapeutics in a report on Friday, March 16th. They issued a “buy” rating and a $15.00 target price for the company.
In related news, CFO Adrian Rawcliffe sold 600,000 shares of the firm’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $1.71, for a total value of $1,026,000.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Peter A. Thompson sold 10,300 shares of the firm’s stock in a transaction dated Monday, May 14th. The stock was sold at an average price of $13.50, for a total transaction of $139,050.00. The disclosure for this sale can be found here. In the last 90 days, insiders bought 9,385,254 shares of company stock valued at $17,966,655 and sold 1,658,367 shares valued at $13,217,821. 26.47% of the stock is currently owned by company insiders.
A number of hedge funds have recently bought and sold shares of ADAP. NEA Management Company LLC increased its holdings in shares of Adaptimmune Therapeutics by 10.9% in the 1st quarter. NEA Management Company LLC now owns 13,332,611 shares of the biotechnology company’s stock valued at $149,725,000 after acquiring an additional 1,306,612 shares during the last quarter. BlackRock Inc. increased its holdings in Adaptimmune Therapeutics by 43,632.6% during the 4th quarter. BlackRock Inc. now owns 787,187 shares of the biotechnology company’s stock valued at $5,258,000 after purchasing an additional 785,387 shares in the last quarter. Millennium Management LLC increased its holdings in Adaptimmune Therapeutics by 83.4% during the 1st quarter. Millennium Management LLC now owns 1,477,641 shares of the biotechnology company’s stock valued at $16,594,000 after purchasing an additional 672,046 shares in the last quarter. Baillie Gifford & Co. increased its holdings in Adaptimmune Therapeutics by 33.6% during the 1st quarter. Baillie Gifford & Co. now owns 2,565,409 shares of the biotechnology company’s stock valued at $28,810,000 after purchasing an additional 644,816 shares in the last quarter. Finally, Foresite Capital Management II LLC acquired a new stake in Adaptimmune Therapeutics during the 1st quarter valued at $4,492,000. 59.95% of the stock is currently owned by institutional investors.
Adaptimmune Therapeutics traded up $0.04, hitting $13.29, during trading on Friday, MarketBeat Ratings reports. 6,503 shares of the company’s stock traded hands, compared to its average volume of 391,811. Adaptimmune Therapeutics has a 52 week low of $4.28 and a 52 week high of $14.63. The firm has a market capitalization of $1.24 billion, a P/E ratio of -16.56 and a beta of 1.17.
Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.04). Adaptimmune Therapeutics had a negative net margin of 160.83% and a negative return on equity of 32.57%. The business had revenue of $4.27 million for the quarter, compared to the consensus estimate of $9.38 million. research analysts anticipate that Adaptimmune Therapeutics will post -0.87 EPS for the current fiscal year.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.